How Technology Is Changing Revenue Management In The Pharmaceutical Industry
Kyle Tierney, Billing and Payments, Strategist, RecVue
Pharmaceutical revenue models are growing more complex, with tiered pricing, parallel trade, rebates, royalties, and large SKU volumes straining spreadsheet-based processes. This article explores how technology is reshaping revenue management, from contract and pricing rules to rebate reconciliation, royalty tracking, and IFRS 15 compliance. It also examines how automation improves revenue visibility, why integration and governance matter, and how finance teams can start with focused problems to reduce errors, limit revenue leakage, and gain a more reliable view of revenue."
Introduction:
Pharmaceutical companies have never had straightforward revenue models. There’s tiered national pricing, parallel trade between EU member states, rebate agreements with payers, royalty arrangements for licensed compounds and huge numbers of SKUs moving through wholesalers and specialist pharmacies.
For years, finance teams have managed much of this complexity with spreadsheets, manual checks and plenty of experience. That approach can work for a while, but as commercial models become more complicated, it becomes harder to keep everything accurate and up to date.
The Growing Role of Technology in Pharmaceutical Revenue Management
The cost of developing new medicines keeps rising. Deloitte's latest analysis of the top 20 global biopharma companies found that the average cost of bringing a drug from discovery to launch reached $2.67 billion in 2025 [1], compared with $2.23 billion the previous year. At the same time, the industry is approaching a significant period of patent expiries [2]. Between 2026 and 2030, hundreds of billions of dollars in branded revenue could be affected as generic and biosimilar competition increases.
That makes the smaller problems in revenue management more important. A billing error might not seem significant on its own, nor might a missed rebate adjustment or a reconciliation that takes longer than it should, but when these issues happen repeatedly across a large business, the financial impact adds up to revenue leakage [3] that is easy to miss in any single reporting period.
This is where technology can help. It isn't about replacing financial judgement, but reducing errors, taking some of the repetitive work out of the process and making it easier to see what’s happening.
Key Areas Where Technology Is Reshaping Revenue Management
1. Contract and Pricing Complexity
Pharma contracts can contain volume discounts, outcomes-based rebates and different pricing arrangements for different countries. European reference pricing systems can make things even more complicated. When teams manage these terms manually, there’s always a risk of applying the wrong rate or missing an important contractual detail.
Revenue management systems can build these rules into the process. Instead of relying on an analyst to remember how a particular agreement should be handled, the relevant terms can be applied as part of billing and revenue calculations.
2. Rebate and Chargeback Management
Rebates owed to payers, group purchasing organisations and distributors can continue long after a sale has taken place. There can also be a large number of agreements to track, each with its own terms. Managing all of this through spreadsheets can slow and complicate reconciliation, especially when claims arrive at different times.
Automation can help match expected rebates and chargebacks against actual claims. Instead of waiting for a quarterly reconciliation exercise to identify differences, finance teams can see what’s happened as information comes in.
3. Royalty and Licensing Revenue
Licensing and co-development agreements have become an important part of the pharmaceutical business model. A single agreement might include different royalty rates, milestone payments and reporting requirements. Multiply that across a portfolio of licensing arrangements and there is a lot for finance teams to track. Technology can bring these terms together and automate parts of the calculation and reporting process. This can reduce manual work and make it easier to identify items that need further attention.
4. Revenue Recognition Compliance
Under IFRS 15 [4], finance teams need to determine when and how different types of revenue should be recognised. Having technology that links recognition schedules to the underlying contract terms can make this process easier to manage.
It also gives finance teams a clearer audit trail. Rather than having to reconstruct how a calculation was reached months later, the relevant information and rules are already connected.
How Data and Automation Are Improving Revenue Visibility
When billing information, rebate data and revenue recognition sit in separate systems, getting a reliable picture can take time. Finance teams may have to pull information from several places and reconcile it before they can work out what the company is actually owed. Automation can bring this information together and provide a more current view of expected and collected revenue. That can be particularly useful for forecasting as pharmaceutical companies use increasingly varied commercial models.
A McKinsey survey reported by CFO Dive [5] found that 98% of CFOs said their departments invested in automation technologies, including AI, over the past year. At the same time, many said their underlying processes were still only partly digitised. This distinction is important. Buying new technology doesn't automatically improve a process. If the underlying information remains fragmented or people still have to move data between systems manually, some of the same problems can remain.
For pharmaceutical companies, there’s plenty at stake. EFPIA estimates that European pharmaceutical R&D investment reached around €60 billion [6] in 2025. With reference pricing, parallel trade, and other pressures affecting commercial margins, finance teams need to ensure their systems provide a reliable picture of revenue.
Building a More Efficient Technology-Driven Revenue Management Strategy
There’s a temptation to try to modernise everything at once. In practice, starting with a specific problem can be more useful. For example, a finance team might begin by looking closely at rebate reconciliation, royalty calculations or revenue recognition. Integration is another important part of the picture. Contract, billing and revenue recognition data need to work together if finance teams are going to get a consistent view. Otherwise, a change in one system can still require a manual update in another system or spreadsheet.
Technology also needs strong governance. Automated processes still need owners. Someone needs to investigate unusual results, handle exceptions and ensure the rules being applied remain correct. That matters particularly in pharma, where pricing arrangements, contracts and commercial models can change regularly.
As pharmaceutical commercial models grow increasingly complex, relying on manual processes and spreadsheets introduces significant financial risk. Adopting dedicated revenue management technology enables finance teams to reduce calculation errors, streamline rebate reconciliations, and maintain strict compliance across global operations.
References:
1. Deloitte – Weight loss drugs boom drives pharma R&D returns. https://www.deloitte.com/uk/en/about/press-room/weight-loss-drugs-boom-drives-pharma-r-and-d-returns.html
2. Pharmaceutical Executive – Patent cliff explained: what it is and how companies navigate it. https://www.pharmexec.com/view/patent-cliff-explained-what-how-companies-navigate
3. RecVue – Revenue leakage: the what, the why, and the how to stop it. https://www.recvue.com/blog/revenue-leakage-the-what-the-why-and-the-how-to-stop-it/
4. IFRS Foundation – IFRS 15 Revenue from Contracts with Customers. https://www.ifrs.org/issued-standards/list-of-standards/ifrs-15-revenue-from-contracts-with-customers/
5. CFO Dive – Many CFOs still in early phase of digital transformation: McKinsey. https://www.cfodive.com/news/many-cfos-still-early-phase-digital-transformation-mckinsey/722091/
6. EFPIA – The Pharmaceutical Industry in Figures 2026. https://www.efpia.eu/media/owqczcqz/the-pharmaceutical-industry-in-figures-2026.pdf
Kyle Tierney is Billing and Payments Strategist at RecVue, bringing over 15 years of experience in enterprise billing, revenue recognition, and partner compensation. Previously at BillingPlatform and Zuora, he worked with global enterprises to design and implement scalable monetization solutions across subscription, consumption, and multi-party revenue models. Kyle specialises in translating complex technical requirements into resilient revenue architectures that support business growth. He holds a degree in Business Administration and Management from Bryant University.
